Related Experiment Video

Updated: Jul 14, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

C-reactive protein and hypertension: is there a causal relationship?

A Virdis1, L Ghiadoni, Y Plantinga

  • 1Department of Internal Medicine, University of Pisa, Pisa, Italy. a.virdis@med.unipi.it

Current Pharmaceutical Design
|June 23, 2007
PubMed

Insights

Inflammation, indicated by C-Reactive Protein (CRP), is linked to cardiovascular events and hypertension. However, the direct causal link between CRP levels and blood pressure remains undiscovered, requiring further research.

Area of Science:

  • Cardiovascular Research
  • Inflammation and Immunology

Background:

  • Inflammation is integral to atherosclerosis development.
  • C-Reactive Protein (CRP) is a key inflammatory marker and predictor of cardiovascular events.
  • Hypertension is strongly associated with inflammatory processes.

Purpose of the Study:

  • To investigate the relationship between C-Reactive Protein (CRP) levels and blood pressure.
  • To explore the potential causal link between inflammation and hypertension.
  • To identify the need for further prospective studies and intervention trials.

Main Methods:

  • Review of existing evidence from experimental and cross-sectional human studies.
  • Analysis of associations between CRP levels and blood pressure, including markers of arterial stiffness.
  • Identification of limitations in current observational data regarding causality.

Main Results:

  • Cross-sectional studies suggest a relationship between CRP levels and blood pressure, particularly systolic blood pressure.
  • CRP is linked to arterial stiffness, indicating a potential interaction.
  • Current evidence from observational studies does not establish a cause-effect relationship.

Conclusions:

  • The causal connection between inflammation (CRP) and blood pressure is not yet definitively established.
  • Prospective studies are needed to clarify the putative causal relationship.
  • Placebo-controlled intervention trials are required to confirm if reducing CRP levels impacts hypertension risk.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...